Firm Highlights
Slide 1 of 6
- Blog
New York State is Set to Impose New Requirements for Separation AgreementsRead more - EventWhen Websites Become Litigation Targets | Digital Risk and Innovation Summit SeriesWebsites can be valuable business assets, but their public availability makes them easy targets for litigation.Read more
- EventDoctor, Doctor, Give Me the News | Hot Town, Summer in the City: What the Washington is Going On?! - Webinar SeriesJoin Polsinelli's public policy team for a three-part lunch and learn series to hear what they’re watching in federal oversight and health care policy this season.Read more
- PublicationFederal Circuit Finds Method-of-Treatment Claims Including In Vivo Dosing Limitations Are Not Enabled By In Vitro DataIn Wyeth LLC v. AstraZeneca Pharmaceuticals LP, the Federal Circuit affirmed judgment as a matter of law that Wyeth's method-of-treatment claims were invalid for lack of enablement, wiping out a $107.5 million jury verdict over AstraZeneca's Tagrisso®.Read more
- NewsPolsinelli Adds Timothy Ayotte in Boston, Strengthening Life Sciences Corporate & Transactional CapabilitiesPolsinelli is pleased to announce that Timothy Ayotte has joined the firm as a shareholder in its Boston office, strengthening the firm’s corporate and transactional depth for life sciences, biotechnology and health care companies.Read more
- Publication2027 OPPS Proposed Rule: Mandatory Provider-Based Attestations Signal a New Compliance EraLast week, the Centers for Medicare & Medicaid Services (CMS) published proposed rules mandating the submission of provider-based attestations for off-campus hospital outpatient departments as part of the 2027 Outpatient Prospective Payment System (OPPS) Proposed Rule (Proposed Rule).Read more